Oncology-focused CRO Pi Health has added a new chef to its executive kitchen by appointing Alex Morozov, M.D., Ph.D., as the company’s first chief medical officer.

Despite izokibep maintaining its newfound winning streak in the clinic, Acelyrin is no longer focusing on its former lead asset as part of a strategic pivot that will see a third of its workforce shown the exit.

Ovid Therapeutics already revealed last month that it was trimming back its headcount as the company navigates an unexpected setback for the Takeda-partnered epilepsy med soticlestat. Now, the biotech has confirmed that it’s halting work on its preclinical programs, including an intravenous (IV) formulation of its seizure drug in order to save cash.

Rivus Pharmaceuticals has plumped up the prospects of its fat-busting, muscle-sparing drug candidate, reporting a primary endpoint hit in a phase 2a trial of people with obesity-related heart failure.

Artificial-intelligence-powered drug designer Absci has joined up with Memorial Sloan Kettering Cancer Center on a project to co-develop as many as six potential antibody therapies in oncology.

The muscle protein titin has long been the titan of the molecular world. Built of more than 34,000 amino acids and weighing in at a hefty 3.7 megadaltons, titin has long been considered the largest protein in the world—until now.

Actinogen Medical’s cortisol blocker has missed the primary endpoint of a phase 2 study in depression, leaving the Australian biotech to focus on its potential in Alzheimer’s disease.

Actinogen Medical’s cortisol blocker has missed the primary endpoint of a phase 2 study in depression, leaving the Australian biotech to focus on its potential in Alzheimer’s disease.

Avidity Biosciences impressed investors with phase 1/2 data in Duchenne muscular dystrophy (DMD) Friday, extending its winning streak in the clinic. But closer examinations of the data revealed details that analysts said present a much more nuanced picture than implied by the headline result.

Antibody-drug conjugates (ADCs) have been at the center of many a billion-dollar biobuck licensing deal over the last year, but Bivictrix Therapeutics feels like it’s been missing out.